David T. Rubin, MD

University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA

Poster(s):

• P1066 - Efficacy and Safety of Guselkumab Through Week 96 After Intravenous or Subcutaneous Induction in Participants With Crohn’s Disease: Phase 3 Long-term Extension Data From GALAXI 2, GALAXI 3, and GRAVITI
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM MT

• P1067 - Segment Level Validation of a Deep Learning Model to Assess Endoscopic Severity in Ulcerative Colitis Using Regulatory-Grade Consensus
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM MT

• P1068 - Restarting Etrasimod After Treatment Interruption Is Not Associated With Cardiovascular Events: Analysis From the ELEVATE UC Clinical Program
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM MT

• P1069 - Mirikizumab Improves Bowel Urgency and Correlates With Patient-Reported Outcomes in Moderately-to-Severely Active Ulcerative Colitis: LUCENT-URGE Trial
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM MT

• P1070 - Artificial Intelligence Assessment of Linear Endoscope Velocity Improves Standardization of Continuous Assessment of Endoscopic Severity in Ulcerative Colitis
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM MT

• P1071 - Efficacy of Etrasimod as First-Line Advanced Treatment Following Failure of Aminosalicylates Only: Data From the ELEVATE UC 52 Phase 3 Clinical Trial
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM MT

• P5307 - Pharmacokinetics and Exposure-Response Relationships of Guselkumab Intravenous or Subcutaneous Induction in Participants With Ulcerative Colitis
  Tuesday, October 28, 2025

  10:30 AM - 4:00 PM MT